Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 June 2025 | Story Tshepo Tsotetsi | Photo Supplied
Dr Herkulaas Combrink
Dr Herkulaas Combrink is representing UFS in a new international research project that aims to improve how evidence is used in public health policymaking.

Dr Herkulaas Combrink, a senior lecturer in the Faculty of Economic and Management Sciences (EMS) at the University of the Free State (UFS), is representing the university in a new international research project that aims to improve how evidence is used in public health policymaking.

Dr Combrink, who is also a co-director of the Interdisciplinary Centre for Digital Futures (ICDF), has been selected as one of the principal investigators in a newly funded project supported by the UK’s International Science Partnerships Fund under the Evidence-Informed Policymaking Programme. Running from April 2025 to March 2026, the project – titled Integrating Evidence for Contextualised Public Health Policy: Lessons from South Africa – explores how different types of evidence can be used more effectively in shaping public health policy. The international collaboration includes researchers from the Centre for Philosophy of Epidemiology, Medicine and Public Health, which is a collaboration between Durham University and the University of Johannesburg; as well as Durham’s Centre for Humanities Engaging Science and Society.

 

From the Free State to global impact

For Dr Combrink, being part of this collaboration highlights the important work being done in the faculty and ICDF that is reaching beyond borders. 

“It’s important to showcase the impact we are making from the Free State that leads to global outcomes,” he said.

The project aims to evaluate an evidence mapping framework to determine how model-based projections and social listening reports can be more effectively integrated and contextualised for policymaking.

“These are two very different data types,” he explained. “The value lies in demonstrating how to apply the framework to different contexts for evidence-based mapping.”

Dr Combrink brings extensive expertise to the team, having worked on both disease modelling and risk communication during South Africa’s COVID-19 response. He was involved in national and provincial social listening initiatives, and used high-frequency social media data to track the spread of misinformation, often referred to as the ‘infodemic.’ 

“We’ve built up enough data within ICDF and EMS to support this study,” he noted.

The goal is not just theoretical. A key outcome of the project is engaging directly with policymakers to refine modelling and risk communication strategies for future pandemics. 

“This will help us to engage with the various departments of health to assist with improving modelling and risk communication work for better social behavioural change,” he explained.

According to Prof Brownhilder Neneh, Vice-Dean for Research and Internationalisation in the EMS faculty, the project reflects the faculty’s growing global presence. 

“Dr Combrink’s participation is a testament to the calibre of scholarship within the faculty,” she said. “It positions EMS as a key contributor to shaping policy and practice with societal impact.”

She added that the collaboration aligns well with the faculty’s vision for global partnerships that are rooted in local relevance.

“By focusing on contextualised evidence for policymaking, this project reflects our commitment to relevance, engagement and global partnership,” she said.

 

What comes next

Over the project’s 12-month timeline, the team will deliver:

• a case study analysis of modelling and social listening during South Africa’s COVID-19 response;
• an extended evidence mapping framework tailored to diverse evidence types;
• policy briefs and practical tools for public health practitioners; and
• a hybrid international workshop in late 2025 bringing together researchers, policymakers and health professionals to test and refine these outputs.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept